Efalizumab viser dosisafhængig nonlineær farmakokinetik, der kan forklares ved dets mættende, specifikke binding til celleoverflade- receptorerne CD11a.
Efalizumab shows dose-dependent nonlinear pharmacokinetics which can be explained by its saturable specific binding to cell surface receptors CD11a.